Evaluating Anorexiants: Benefits, Risks, and Future Directions in Obesity Treatment

Gloria Ferranti*

Department of Animal Pathology, University of Las Palmas de Gran Canaria, Spain

Abstract

Anorexiants, also known as appetite suppressants, play a pivotal role in the management of obesity by aiding weight reduction through the suppression of appetite. This paper evaluates the efcacy, benefts, and risks associated with anorexiants, and explores future directions for their use in obesity treatment. The review synthesizes fndings from recent clinical trials, meta-analyses, and observational studies to assess the efectiveness of various anorexiants, including both approved medications and those in development. Key benefts of anorexiants A includi
improved profles. Future directions include the exploration of novel anorexiants with targeted mechanisms, combination therapies, and the integration of anorexiants with lifestyle interventions to optimize weight management outcomes. By addressing current limitations and focusing on innovative approaches, the feld of anorexiants can contribute more efectively to obesity treatment and management.

Keywords:

E

Introduction

1.

2.

3-5.

Materials and Methods

Conclusion

Acknowledgement

Conflict of Interest

References

1. Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, et al. (2016) Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol 11: 1082-1089.

2. Zampieri S, Cattarossi S, Bembi B, Dardis A (2017) GBA1 Analysis in Next-Generation Era: Pitfalls, Challenges, and Possible Solutions. J Mol Diagnost 19: 733-741.

3. Jilwan MN (2020) Imaging features of mucopolysaccharidoses in the head and neck. Int J Pediatr Otorhinolaryngol 134: 110022.

4. Grabowski GA (2012) Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program 2012: 13-8.

5. Yoshida S, Kido J, Matsumoto S, Momosaki K, Mitsubuchi H, et al. (1990) Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr Int 58: 946-9.

6. Bultron G, Kacena K, Pearson D, Boxer M, Yang M, et al. (2010) The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 33: 167-173.

7. Horowitz M, Wilder S, Horowitz Z, Reiner O, Gelbart T, et al. (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4: 87-96.

8. Winfeld SL, Tayebi N, Martin BM, Ginns EI, Sidransky E et al. (1997) Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res 7: 1020-1026.

9. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, et al. (2000) Analysis